The Journal of Practical Medicine ›› 2024, Vol. 40 ›› Issue (24): 3561-3567.doi: 10.3969/j.issn.1006-5725.2024.24.020
• Reviews • Previous Articles Next Articles
Received:
2024-08-26
Online:
2024-12-25
Published:
2024-12-23
Contact:
Hao. ZHANG
E-mail:hawerchina@gmail.com
CLC Number:
Hang DENG,Hao. ZHANG. Clinical application of hepatocellular carcinoma prediction models: current challenges and future directions[J]. The Journal of Practical Medicine, 2024, 40(24): 3561-3567.
Tab.1
Basic information statistics of hepatocellular carcinoma diagnosis and prediction model"
模型 | 发表 年份 | 开发人群信息 | 纳入指标 | ||
---|---|---|---|---|---|
患者数量 | 患者地区 | 患者种类 | |||
GALAD | 2014 | 670 | 英国 | CLD患者及HCC患者 | 年龄、性别、AFP、AFP-L3、DCP |
aMAP | 2020 | 3 688 | 中国 | 经治疗CHB患者 | 年龄、性别、白蛋白、胆红素、PLT |
REACH-B | 2011 | 3 584 | 亚洲 | 未经治疗CHB患者 | 年龄、性别、HBeAg、HBV、DNA、ALT |
PAGE-B | 2016 | 1 325 | 欧洲 | 经ETV或TDF治疗的CHB患者 | 年龄、性别、PLT |
REAL-B | 2019 | 5 365 | 美国、亚洲 | 经治疗CHB患者 | 年龄、性别PLT、AFP、糖尿病、 肝硬化、饮酒 |
GAAD | 2023 | 1 084 | 中国、德国、西班牙、泰国 | HCC患者以及CLD患者 | PIVKA-Ⅱ、AFP、年龄和性别 |
ASAP | 2019 | 2 198 | 中国 | HCC患者、CHB患者、HBV导致的肝硬化患者、 良性肝肿瘤患者以及健康人群 | PIVKA-Ⅱ、AFP、年龄和性别 |
1 |
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. doi:10.3322/caac.21492
doi: 10.3322/caac.21492 |
2 | 鲜林峰, 方乐天, 刘文斌, 等. 原发性肝癌流行现状、主要发病机制及防控策略[J]. 中国癌症防治杂志, 2022,14(3):320-328. |
3 |
YANG J D, HAINAUT P, GORES G J, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019,16(10):589-604. doi:10.1038/s41575-019-0186-y
doi: 10.1038/s41575-019-0186-y |
4 |
SINGAL A G, KANWAL F, LLOVET J M. Global trends in hepatocellular carcinoma epidemiology: Implications for screening, prevention and therapy[J]. Nat Rev Clin Oncol, 2023,20(12):864-884. doi:10.1038/s41571-023-00825-3
doi: 10.1038/s41571-023-00825-3 |
5 |
JOHNSON P, ZHOU Q, DAO D Y, et al. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2022,19(10):670-681. doi:10.1038/s41575-022-00620-y
doi: 10.1038/s41575-022-00620-y |
6 | European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018,69(1):182-236. |
7 |
COLLINS G S, REITSMA J B, ALTMAN D G, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement[J]. BMJ, 2015,350:g7594. doi:10.1136/bmj.g7594
doi: 10.1136/bmj.g7594 |
8 |
ALBA A C, AGORITSAS T, WALSH M, et al. Discrimination and Calibration of Clinical Prediction Models: Users' Guides to the Medical Literature[J]. JAMA, 2017,318(14):1377-1384. doi:10.1001/jama.2017.12126
doi: 10.1001/jama.2017.12126 |
9 |
STEYERBERG E W, VERGOUWE Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation[J]. Eur Heart J, 2014,35(29):1925-1931. doi:10.1093/eurheartj/ehu207
doi: 10.1093/eurheartj/ehu207 |
10 |
JOHNSON P J, PIRRIE S J, COX T F, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers[J]. Cancer Epidemiol Biomarkers Prev, 2014,23(1):144-153. doi:10.1158/1055-9965.epi-13-0870
doi: 10.1158/1055-9965.epi-13-0870 |
11 |
李鸿江. 基于血清学标志物的肝癌风险预测模型研究[D]. 北京:北京化工大学, 2022. doi:10.3760/cma.j.cn114452-20220315-00150
doi: 10.3760/cma.j.cn114452-20220315-00150 |
12 |
HANIF H, ALI M J, SUSHEELA A T, et al. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma[J]. World J Gastroenterol, 2022,28(2):216-229. doi:10.3748/wjg.v28.i2.216
doi: 10.3748/wjg.v28.i2.216 |
13 |
ZHANG Y S, CHU J H, CUI S X, et al. Des-gamma-carboxy prothrombin (DCP) as a potential autologous growth factor for the development of hepatocellular carcinoma[J]. Cell Physiol Biochem, 2014,34(3):903-915. doi:10.1159/000366308
doi: 10.1159/000366308 |
14 |
BEST J, BECHMANN L P, SOWA J P, et al. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis[J]. Clin Gastroenterol Hepatol, 2020,18(3):728-735. doi:10.1016/j.cgh.2019.11.012
doi: 10.1016/j.cgh.2019.11.012 |
15 |
GUAN M C, ZHANG S Y, DING Q, et al. The Performance of GALAD Score for Diagnosing Hepatocellular Carcinoma in Patients with Chronic Liver Diseases: A Systematic Review and Meta-Analysis[J]. J Clin Med, 2023,12(3):949. doi:10.3390/jcm12030949
doi: 10.3390/jcm12030949 |
16 |
SCHOTTEN C, OSTERTAG B, SOWA J P, et al. GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients[J]. Pharmaceuticals (Basel), 2021,14(8):735. doi:10.3390/ph14080735
doi: 10.3390/ph14080735 |
17 | WANG Y, WANG M, LI H, et al. A male-ABCD algorithm for hepatocellular carcinoma risk prediction in HBsAg carriers[J]. Chin J Cancer Res, 2021,33(3):352-363. |
18 |
SINGAL A G, TAYOB N, MEHTA A, et al. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis[J]. Hepatology, 2022,75(3):541-549. doi:10.1002/hep.32185
doi: 10.1002/hep.32185 |
19 | 李慧泉. 福清市高山镇HBV感染者肝癌预测风险GALAD评分相关影响因素的研究[D]. 福州:福建医科大学, 2021. |
20 | 黄晨军, 肖潇, 周琳, 等. 肝癌三项(AFP、AFP-L3%、DCP)与GALAD、类GALAD模型临床应用专家共识[J]. 检验医学, 2023,38(7):607-623. |
21 |
FAN R, PAPATHEODORIDIS G, SUN J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol, 2020,73(6):1368-1378. doi:10.1016/j.jhep.2020.07.025
doi: 10.1016/j.jhep.2020.07.025 |
22 | 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 浙江实用医学, 2022,27(6):528-536. |
23 | 喻苧. aMAP评分联合肝脏硬度值测定可准确评估慢性乙型肝炎患者抗病毒治疗前后的肝纤维化[D]. 广州:南方医科大学, 2023. |
24 |
FAN R, CHEN L, ZHAO S, et al. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures[J]. J Hepatol, 2023,79(4):933-944. doi:10.1016/j.jhep.2023.05.039
doi: 10.1016/j.jhep.2023.05.039 |
25 |
YANG H I, YUEN M F, CHAN H L, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score[J]. Lancet Oncol, 2011,12(6):568-574. doi:10.1016/s1470-2045(11)70077-8
doi: 10.1016/s1470-2045(11)70077-8 |
26 |
WU S, ZENG N, SUN F, et al. Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation[J]. Clin Gastroenterol Hepatol, 2021,19(12):2499-2513. doi:10.1016/j.cgh.2021.02.040
doi: 10.1016/j.cgh.2021.02.040 |
27 |
KIM H Y, LAMPERTICO P, NAM J Y, et al. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B[J]. J Hepatol, 2022,76(2):311-318. doi:10.1016/j.jhep.2021.09.025
doi: 10.1016/j.jhep.2021.09.025 |
28 |
PAPATHEODORIDIS G, DALEKOS G, SYPSA V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy[J]. J Hepatol, 2016,64(4):800-806. doi:10.1016/j.jhep.2015.11.035
doi: 10.1016/j.jhep.2015.11.035 |
29 |
COSTA A, DA S M, CASTRO R S, et al. PAGE-B and REACH-B Predicts the Risk of Developing Hepatocellular Carcinoma in Chronic Hepatitis B Patients from Northeast, Brazil[J]. Viruses, 2022,14(4):732. doi:10.3390/v14040732
doi: 10.3390/v14040732 |
30 |
GOKCEN P, GUZELBULUT F, ADALI G, et al. Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment[J]. World J Gastroenterol, 2022,28(6):665-674. doi:10.3748/wjg.v28.i6.665
doi: 10.3748/wjg.v28.i6.665 |
31 |
YANG H I, YEH M L, WONG G L, et al. Real-world effectiveness from the Asia Pacific Rim liver consortium for HBV risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy[J]. J Infect Dis, 2020,221(3):389-399. doi:10.1093/infdis/jiz477
doi: 10.1093/infdis/jiz477 |
32 |
PIRATVISUTH T, HOU J, TANWANDEE T, et al. Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies[J]. Hepatol Commun, 2023,7(11):e0317. doi:10.1097/hc9.0000000000000317
doi: 10.1097/hc9.0000000000000317 |
33 |
POTE N, CAUCHY F, ALBUQUERQUE M, et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion[J]. J Hepatol, 2015,62(4):848-854. doi:10.1016/j.jhep.2014.11.005
doi: 10.1016/j.jhep.2014.11.005 |
34 |
中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J].中国实用外科杂志,2024,44(4):361-386. doi:10.3877/cma.j.issn.2095-3232.2024.04.001
doi: 10.3877/cma.j.issn.2095-3232.2024.04.001 |
35 |
YANG T, XING H, WANG G, et al. A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B[J]. Clin Chem, 2019,65(12):1543-1553. doi:10.1373/clinchem.2019.308965
doi: 10.1373/clinchem.2019.308965 |
36 | 周宁杰. 恩替卡韦抗病毒治疗对肝癌HBV感染患者的疗效及其对HBV-DNA和肝功能水平的影响[J]. 抗感染药学, 2019,16(1):113-116. |
37 |
YUEN M F, AHN S H, CHEN D S, et al. Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations[J]. J Clin Gastroenterol, 2016,50(4):286-294. doi:10.1097/mcg.0000000000000478
doi: 10.1097/mcg.0000000000000478 |
38 | 赫捷, 陈万青, 沈洪兵, 等. 中国人群肝癌筛查指南(2022,北京)[J]. 临床肝胆病杂志, 2022,38(8):1739-1758. |
39 | 牛一鸣. 代谢综合征与肝癌早期复发的相关性研究[D]. 银川:宁夏医科大学, 2022. |
40 |
IGUCHI K, SADA R, MATSUMOTO S, et al. DKK1-CKAP4 signal axis promotes hepatocellular carcinoma aggressiveness[J]. Cancer Sci, 2023,114(5):2063-2077. doi:10.1111/cas.15743
doi: 10.1111/cas.15743 |
41 |
XU J, AN P, WINKLER C A, et al. Dysregulated microRNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: Potential as Biomarkers and Therapeutic Targets[J]. Front Oncol, 2020,10:1271. doi:10.3389/fonc.2020.01271
doi: 10.3389/fonc.2020.01271 |
42 |
ZHOU F, SHANG W, YU X, et al. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment[J]. Med Res Rev, 2018,38(2):741-767. doi:10.1002/med.21455
doi: 10.1002/med.21455 |
43 | 曾繁利, 王东和, 苏锐, 等. AFP、AFP-L3和DKK1联合检测对原发性肝癌的诊断价值[J]. 川北医学院学报, 2020,35(1):130-132. |
44 | 郑睿颖, 刘根焰. 机器学习在感染性疾病临床预测模型中的应用进展[J]. 中国血吸虫病防治杂志, 2023,35(3):317-321. |
45 | 黄良江, 毛德文, 郑景辉, 等. 人工智能在肝性脑病风险预测模型中的应用进展[J]. 实用医学杂志, 2024,40(3):289-294. |
46 |
IOANNOU G N, TANG W, BESTE L A, et al. Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis[J]. JAMA Netw Open, 2020,3(9):e2015626. doi:10.1001/jamanetworkopen.2020.15626
doi: 10.1001/jamanetworkopen.2020.15626 |
47 |
HEATON H, FUNG S W. Explainable AI via learning to optimize[J]. Sci Rep, 2023,13(1):10103. doi:10.1038/s41598-023-36249-3
doi: 10.1038/s41598-023-36249-3 |
48 |
SHI Y, ZHU C, QI W, et al. Critical appraisal and assessment of bias among studies evaluating risk prediction models for in-hospital and 30-day mortality after percutaneous coronary intervention: a systematic review[J]. BMJ Open, 2024,14(6):e85930. doi:10.1136/bmjopen-2024-085930
doi: 10.1136/bmjopen-2024-085930 |
49 |
OKADA Y, NING Y, ONG M. Explainable artificial intelligence in emergency medicine: an overview[J]. Clin Exp Emerg Med, 2023,10(4):354-362. doi:10.15441/ceem.23.145
doi: 10.15441/ceem.23.145 |
50 | 王梓屹, 简萌, 李彬, 等. 2023年可解释人工智能技术主要发展动向分析[J]. 无人系统技术, 2024,7(2):113-120. |
51 |
DESHPANDE P, RASIN A, TCHOUA R, et al. Biomedical heterogeneous data categorization and schema mapping toward data integration[J]. Front Big Data, 2023,6:1173038. doi:10.3389/fdata.2023.1173038
doi: 10.3389/fdata.2023.1173038 |
52 |
ELMORE J G, LEE C I. Data Quality, Data Sharing, and Moving Artificial Intelligence Forward[J]. JAMA Netw Open, 2021,4(8):e2119345. doi:10.1001/jamanetworkopen.2021.19345
doi: 10.1001/jamanetworkopen.2021.19345 |
53 | 姚仁玲, 朱艺璇, 黄睿, 等. 维生素摄入量与代谢相关脂肪性肝病进程的相关性分析[J]. 实用医学杂志, 2024,40(6):820-826. |
54 | 黄庆, 邹旻红, 李旺林, 等. 左右半结肠黏液腺癌术后患者生存特征分析:一项基于SEER数据库的研究[J]. 实用医学杂志, 2021,37(10):1351-1356. |
55 | 吕艺蓁, 孙世权. 2023年度肿瘤单细胞与空间多组学研究进展盘点[J]. 中国癌症防治杂志, 2024,16(1):17-22. |
56 |
AL-KUHALI H A, SHAN M, HAEL M A, et al. Multiview clustering of multi-omics data integration by using a penalty model[J]. BMC Bioinformatics, 2022,23(1):288. doi:10.1186/s12859-022-04826-4
doi: 10.1186/s12859-022-04826-4 |
57 | 刘晓帆, 鲁志. 复杂疾病中多组学多模态数据的生物信息学研究进展[J]. 科学通报, 2024,69(30):4432-4446. |
58 |
SATHYANARAYANAN A, MUELLER T T, ALI M M, et al. Multi-omics data integration methods and their applications in psychiatric disorders[J]. Eur Neuropsychopharmacol, 2023,69:26-46. doi:10.1016/j.euroneuro.2023.01.001
doi: 10.1016/j.euroneuro.2023.01.001 |
[1] | Xiaomei CHEN,Anqi WANG,Jizhen YANG,Miao YU. Prognosis and immune correlation analysis of m1A/m5C/m6A/m7G regulated genes in gastric cancer [J]. The Journal of Practical Medicine, 2024, 40(9): 1230-1237. |
[2] | Shihe XIAO,Gang LI,Zhonghai LIU,Zhen. LIU. Expression of ZEB2 and CCL20 in glioma tissue and their correlation with prognosis [J]. The Journal of Practical Medicine, 2024, 40(9): 1262-1267. |
[3] | Futao DANG,Yingmei TANG,Haiyan FU,Huanlong LI,Jiamin XU,Xu. TAN. The efficacy of artificial (nonbiological) extracorporeal liver support system for primary biliary cholangitis and the effect of this therapy on prognosis [J]. The Journal of Practical Medicine, 2024, 40(7): 955-961. |
[4] | Xiya MA,Hu JI,Zehua ZHU,Bo PAN,Qiang XIE,Xiaobo. YAO. The predictive value of 18F⁃FDG PET/CT metabolic heterogeneity parameters combined with clinical features for the prognosis of esophageal squamous cell carcinoma before definitive radiochemotherapy [J]. The Journal of Practical Medicine, 2024, 40(7): 966-971. |
[5] | Fazhu FEI,Jiajun LU,Shuai ZHANG,Hao LI,Bin REN. Clinical application progress of immunization and targeted therapy for Hepatocellular Carcinoma in special populations [J]. The Journal of Practical Medicine, 2024, 40(6): 738-742. |
[6] | Zhipeng WU,Yuqin ZHANG,Minggang WANG,Rongzhen ZHANG,Dewen. MAO. Expression and biological function of TRP signaling pathway in hepatocellular carcinoma [J]. The Journal of Practical Medicine, 2024, 40(6): 743-747. |
[7] | Yuxin CHENG,Liang LIU,Shiyu DONG,Shengchao LI,Meng ZHANG. Research advances in exosomal proteins, mRNA and non⁃coding RNA regulation of Hepatocellular Carcinoma [J]. The Journal of Practical Medicine, 2024, 40(6): 748-755. |
[8] | Junhong XU,Hongbing YAO,Xueyao WANG,Wei GUO,Caijin LU,Jiaxing WU,Jianhui JIANG,Dongkang ZHAO. Clinical efficacy of FOLFOX⁃HAIC combined with lenvatinib and PD⁃1 inhibitor in the treatment of intermediate and advanced Hepatocellular Carcinoma [J]. The Journal of Practical Medicine, 2024, 40(6): 762-767. |
[9] | Lu YAN,Tianwei SHI. Expression of nicastrin, N1ICD and hes1 proteins in normal and cancerous liver tissues of mice [J]. The Journal of Practical Medicine, 2024, 40(6): 768-772. |
[10] | Weifeng LIU,Zheng DAI,Yibin ZHOU,Kaiwen FENG,Kai WEI,Gule SUN,Dongrong YANG,Jin. ZHU. The value of urine protein kinase Y⁃linked gene promoter site methylation in early diagnosis of prostate cancer [J]. The Journal of Practical Medicine, 2024, 40(5): 688-694. |
[11] | Sibo LONG,Yan CHEN,Xintong ZHANG,Yanjun YIN,Limei YANG,Maike ZHENG,Chaohong WANG,Qing SUN,Jun YAN,Yiheng SHI,Guangli SHI,Yan ZHAO,Guirong. WANG. Serum levels of procalcitonin, interleukin⁃6 and interleukin⁃8 in patients with COVID⁃19 infection at admission and their significance in patient prognosis [J]. The Journal of Practical Medicine, 2024, 40(4): 471-475. |
[12] | Zixu SONG,Guangzheng ZHU,Chenxu GUO,Jiaqi WU,Ligong ZHANG,Jun. QIAN. Expression of SLC35A2 and PFDN2 in breast cancer and its relationship with clinical observables and prognosis [J]. The Journal of Practical Medicine, 2024, 40(4): 496-502. |
[13] | Yichen WANG,Yanwen YAN,Meihui SONG,Xiangjun XUE,Wenguang ZHOU,Yuquan LI,Ling QI,Guanghua LI,Xiangzong ZENG. Clinical significance of HOXB4 gene expression levels in myelodysplastic syndromes [J]. The Journal of Practical Medicine, 2024, 40(3): 321-325. |
[14] | Jia CUI,Mingming ZHANG,Na WANG,Wei GAO,Fei LI. Correlation analysis of glucose and lipid metabolism indicators combined with antiphospholipid antibodies on prognosis of patients with atherosclerosis [J]. The Journal of Practical Medicine, 2024, 40(3): 326-329. |
[15] | Shuang CHEN,Na YANG,Yudong HUANG,Xiangfeng KONG,Jintao LI,Yizhong TANG,Kexiong MA,Yangyang ZHANG,Yuandong ZHANG,Chengde REN. Relationship between serum miR-21 and miR-27b levels and prognosis of patients with renal clear cell carcinoma [J]. The Journal of Practical Medicine, 2024, 40(3): 343-348. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||